← FDA DRUG APPROVALS

FDA NDA · NDA217766

VASOPRESSIN IN 0.9% SODIUM CHLORIDE

vasopressin

Sponsor: LONG GROVE PHARMS

APPLICATION
NDA217766
TYPE
NDA
ORIGINAL APPROVAL
2024-07-11
LATEST ACTION
2024-07-11
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription, Discontinued

Products

VASOPRESSIN IN SODIUM CHLORIDE 0.9% · ReferencePrescription
VASOPRESSIN 40UNITS/100ML (0.4UNITS/ML) · SOLUTION · INTRAVENOUS
VASOPRESSIN IN SODIUM CHLORIDE 0.9% · ReferenceDiscontinued
VASOPRESSIN 50UNITS/50ML (1UNIT/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION · INTRAVENOUS
VASOPRESSIN IN SODIUM CHLORIDE 0.9% · ReferencePrescription
VASOPRESSIN 20UNITS/100ML (0.2UNITS/ML) · SOLUTION · INTRAVENOUS

Approval history

2024-07-11Type 3 - New Dosage Form · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →